|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
100 项与 Triphase Research and Development III Corp. 相关的临床结果
0 项与 Triphase Research and Development III Corp. 相关的专利(医药)
100 项与 Triphase Research and Development III Corp. 相关的药物交易
100 项与 Triphase Research and Development III Corp. 相关的转化医学